The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Ouro Medicines’ experimental treatment gamgertamig for autoimmune hemolytic anemia (AIHA), a group of autoimmune diseases that includes cold agglutinin disease. Fast-track designation is intended to accelerate the development and review of potential treatments for serious diseases…
People with cold agglutinin disease (CAD) treated long-term with Enjaymo (sutimlimab-jome) maintained stable hemoglobin levels, avoided blood transfusions, and showed sustained reductions in red blood cell destruction for nearly two years, according to a real-world, single-center study from Germany. “The present small, [single-center]…
Discussion
First in a series. I woke up earlier than usual for my first day back at the Spencer Cancer Center in Alabama. But as my anemia has gotten worse, getting dressed takes much longer than usual, because I have to rest often. But my ride was coming at 7:30…
A man and a woman in China were found to have a type of fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL) as the underlying cause of their autoimmune hemolytic anemia (AIHA), a group of disorders in which the immune system attacks and destroys red blood cells, according to…
Discussion
“Here is Edward Bear, coming downstairs now, bump, bump, bump, on the back of his head, behind Christopher Robin. It is, as far as he knows, the only way of coming downstairs, but sometimes he feels that there really is another way, if only he could stop bumping for a…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
